DDInter927 DDInter1032
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Lefamulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lefamulin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Octreotide
Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Lefamulin may lead to a major life threatening interaction when taken with Macimorelin